- Previous Close
0.4245 - Open
0.4240 - Bid 0.4235 x --
- Ask 0.4240 x --
- Day's Range
0.4205 - 0.4250 - 52 Week Range
0.1136 - 0.4350 - Volume
4,151,278 - Avg. Volume
5,069,929 - Market Cap (intraday)
682.631M - Beta (5Y Monthly) 1.26
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0700 - Earnings Date Feb 21, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Abliva AB (publ) discovers and develops medicines for the treatment of mitochondrial disease in Sweden. The company is developing KL1333 that is in Phase 2 clinical trial to treat chronic fatigue and myopathy in genetically confirmed adult patients with primary mitochondrial disease; and NV354, which has completed preclinical development for the treatment of mitochondrial disease with neurologic complications. It has a licensing and collaboration agreement with Owl Therapeutics for NeuroSTAT for the treatment of traumatic brain injury; and Yungjin Pharm on the clinical development of the KL1333, as well as Isomerase, Children's Hospital of Philadelphia, Newcastle University and University College London, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
abliva.comRecent News: ABLI.ST
View MorePerformance Overview: ABLI.ST
Trailing total returns as of 1/7/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ABLI.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ABLI.ST
View MoreValuation Measures
Market Cap
684.24M
Enterprise Value
637.43M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.76k
Price/Book (mrq)
7.80
Enterprise Value/Revenue
4.65k
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-53.08%
Return on Equity (ttm)
-104.31%
Revenue (ttm)
137k
Net Income Avi to Common (ttm)
-102.12M
Diluted EPS (ttm)
-0.0700
Balance Sheet and Cash Flow
Total Cash (mrq)
45.25M
Total Debt/Equity (mrq)
0.32%
Levered Free Cash Flow (ttm)
-22.35M